Man Group PLC Exelixis, Inc. Transaction History

Man Group PLC

$36 Billion
Q3 2024

A detailed history of Man Group PLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Man Group PLC holds 297,710 shares of EXEL stock, worth $10.7 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

297,710

Previous 474,093 37.2%

Holding current value

$10.7 Million

Previous $10.7 Million 27.48%

% of portfolio

0.02%

Previous 0.03%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$21.96 - $27.6 $3.87 Million - $4.87 Million	-176,383 Reduced 37.2%	297,710 $7.73 Million
Q2 2024 Aug 14, 2024	SELL	$20.34 - $23.73 $3.76 Million - $4.38 Million	-184,766 Reduced 28.04%	474,093 $10.7 Million
Q1 2024 May 15, 2024	SELL	$20.17 - $23.93 $2.07 Million - $2.45 Million	-102,518 Reduced 13.46%	658,859 $15.6 Million
Q4 2023 Feb 14, 2024	BUY	$19.25 - $24.13 $4.2 Million - $5.26 Million	217,930 Added 40.1%	761,377 $18.3 Million
Q3 2023 Nov 14, 2023	BUY	$19.04 - $22.74 $8.38 Million - $10 Million	440,342 Added 427.08%	543,447 $11.9 Million
Q2 2023 Aug 14, 2023	BUY	$18.17 - $20.48 $576,479 - $649,768	31,727 Added 44.45%	103,105 $1.97 Million
Q1 2023 May 15, 2023	SELL	$16.3 - $19.41 $13.4 Million - $16 Million	-823,901 Reduced 92.03%	71,378 $1.39 Million
Q4 2022 Feb 14, 2023	BUY	$14.96 - $17.39 $89,909 - $104,513	6,010 Added 0.68%	895,279 $14.4 Million
Q3 2022 Nov 14, 2022	SELL	$15.68 - $22.27 $1.77 Million - $2.51 Million	-112,873 Reduced 11.26%	889,269 $13.9 Million
Q2 2022 Aug 15, 2022	BUY	$17.44 - $23.16 $11.8 Million - $15.7 Million	678,485 Added 209.63%	1,002,142 $20.9 Million
Q1 2022 May 16, 2022	BUY	$17.03 - $22.67 $2.49 Million - $3.32 Million	146,314 Added 82.5%	323,657 $7.34 Million
Q4 2021 Feb 14, 2022	BUY	$15.84 - $21.88 $1.67 Million - $2.31 Million	105,462 Added 146.72%	177,343 $3.24 Million
Q3 2021 Nov 15, 2021	BUY	$16.3 - $21.14 $736,450 - $955,126	45,181 Added 169.22%	71,881 $1.52 Million
Q2 2021 Aug 16, 2021	SELL	$17.95 - $25.56 $100,143 - $142,599	-5,579 Reduced 17.28%	26,700 $486,000
Q1 2021 May 17, 2021	BUY	$20.53 - $25.22 $128,784 - $158,205	6,273 Added 24.12%	32,279 $729,000
Q4 2020 Feb 16, 2021	SELL	$18.39 - $24.8 $7.04 Million - $9.49 Million	-382,602 Reduced 93.64%	26,006 $522,000
Q3 2020 Nov 16, 2020	SELL	$20.67 - $26.94 $683,556 - $890,905	-33,070 Reduced 7.49%	408,608 $9.99 Million
Q2 2020 Aug 14, 2020	SELL	$16.46 - $27.42 $853,549 - $1.42 Million	-51,856 Reduced 10.51%	441,678 $10.5 Million
Q1 2020 May 15, 2020	SELL	$14.46 - $21.8 $2.27 Million - $3.42 Million	-157,019 Reduced 24.14%	493,534 $8.5 Million
Q4 2019 Feb 18, 2020	BUY	$15.15 - $18.89 $3.46 Million - $4.31 Million	228,060 Added 53.98%	650,553 $11.5 Million
Q3 2019 Nov 14, 2019	BUY	$17.68 - $22.65 $4.7 Million - $6.02 Million	265,894 Added 169.79%	422,493 $7.47 Million
Q2 2019 Aug 14, 2019	BUY	$18.93 - $24.75 $1.96 Million - $2.56 Million	103,477 Added 194.79%	156,599 $3.35 Million
Q1 2019 May 15, 2019	BUY	$19.6 - $24.76 $156,290 - $197,436	7,974 Added 17.66%	53,122 $1.27 Million
Q4 2018 Feb 14, 2019	SELL	$13.65 - $21.8 $240,048 - $383,374	-17,586 Reduced 28.03%	45,148 $888,000
Q3 2018 Nov 14, 2018	BUY	$15.87 - $22.4 $546,737 - $771,702	34,451 Added 121.81%	62,734 $1.11 Million
Q2 2018 Aug 14, 2018	SELL	$18.56 - $22.45 $443,918 - $536,959	-23,918 Reduced 45.82%	28,283 $608,000
Q1 2018 May 15, 2018	BUY	$22.15 - $31.89 $1.16 Million - $1.66 Million	52,201 New	52,201 $1.16 Million

Others Institutions Holding EXEL

# of Institutions

503

Shares Held

244M

Call Options Held

2.54M

Put Options Held

2.29M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.6B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Account